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Eosinophilic  oesophagitis  is  a chronic  inﬂammatory  disease  characterized  by eosinophilic  inﬁltration  of
the  oesophageal  mucosa.  Food  and  aero-allergens  are  involved  in its  pathogenesis.  Dysphagia  and  food
impaction  are  the dominant  symptoms  in  adult  with  eosinophilic  oesophagitis.  However,  a  wide  range
of symptoms  has  been  noticed  such  as  chest  pain or  gastro-oesophageal  reﬂux  disease-like  symptoms.
Upper  gastro-intestinal  endoscopy  and oesophageal  biopsies  are  crucial  for  the  diagnosis  of  eosinophilic
oesophagitis.  Endoscopy  might  be  normal  or reveal  typical  patterns  such  as rings,  furrows,  exudates,
oedema,  and  stricture.  Two  to  four biopsies  should  be  performed  both  in the  distal  and  in the  proximal
oesophagus,  and 15  eosinophils  per  high  power  ﬁeld  within  the  oesophageal  epithelium  are  the minimal
threshold  to diagnose  eosinophilic  oesophagitis.  Allergy  testing  is  recommended,  although  its impact
to  orient  treatment  remains  to  be demonstrated.  Eosinophilic  oesophagitis  treatment  includes  medi-
cal  treatment,  diet  and  endoscopic  dilation.  Proton  pump  inhibitors  are  the  ﬁrst-line  therapy  as  some
eosinophilic  oesophagitis  phenotypes  respond  well  to proton  pump  inhibitors.  Topical  viscous  cortico-
steroids  or  diet elimination  are the  treatment  of  choice.  There  is no clear  evidence  in the  literature  to
prefer  one  to the  other.  Finally  endoscopic  dilation  should  be  considered  in  case  of persistent  symptomatic
stenosis  despite  medical  therapy.
 Gast© 2013 Editrice
. Introduction
Eosinophilic inﬁltration of the oesophagus was  ﬁrst described
n adults with dysphagia in the 1990s [1]. It was  recognized as
eing different from gastro-oesophageal reﬂux disease (GERD). A
ecent international consensus deﬁned eosinophilic oesophagitis
EoE) as “a chronic, immune/antigene-mediated disease character-
zed clinically by symptoms related to oesophageal dysfunction and
istologically by eosinophil-predominant inﬂammation”.
Since the ﬁrst description, EoE incidence has dramatically
ncreased [2,3]. The prevalence is estimated around 43–55 per
00,000 inhabitants in Western countries. A recent study based on
ong-term follow-up tends to prove that there is a true increase of
ncidence and not only a better recognition by both gastroenterol-
gists and pathologists [3].Eosinophilic oesophagitis seems to be more frequent in young
dult males even if it may  affect individuals at any age. Thus, age
s a predictive factor of EoE in patients with dysphagia. Among
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outpatients who  underwent endoscopy for dysphagia at the Mayo
Clinic in Rochester, age younger than 47 years was an independent
predictive factor of EoE (odds ratio 0.94, 95% conﬁdence interval
0.90–0.98, p = 0.01) [4]. In Olten county in Switzerland, the inci-
dence of EoE was  lower in women  than men (relative risk = 0.585,
95% conﬁdence interval 0.331–1.034, p = 0.065) [3]. In this popula-
tion the sex ratio female/female was  3:1.
The aims of this review were to give a general update of this
newly recognized entity including pathophysiology, clinical pre-
sentation, diagnostic modalities and treatment.
2. Physiopathology
Eosinophilic oesophagitis is characterized by an eosinophil
inﬁltration within the oesophageal epithelium, and T-helper 2
(Th2)-type immune responses, which are typical of other atopic
conditions. The inﬂammatory response is restricted to the oesoph-
agus and does not involve the stomach and the duodenum.2.1. Inﬂammatory process of oesophageal epithelium
In EoE, the oesophageal epithelium is inﬁltrated not only by
eosinophils but also by T-cells, B cells and mast cells [5]. Increased
 Ltd. All rights reserved.
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Table 1
Clinical features of eosinophilic oesophagitis in children and adults.
Gastrointestinal symptoms Atypical symptoms
Dysphagia (adolescents and adults) Chest pain
Food impaction (adolescents and adults) Rhinitis
Heartburn Asthma
Regurgitations Hoarseness
Abdominal pain Croup, cough
Feeding disorders (paediatric < 2 years) Rhinosinusitis72 S. Roman et al. / Digestive an
umbers of denditric cells have also been observed in oesophageal
pithelium of patients with EoE.
Increased levels of cytokines such as IL-4, IL-5, IL-9 and IL-13
ave been noticed in oesophageal mucosa of patients with EoE [6,7].
hese cytokines activate eosinophils, mast cells and B cells.
Oesophageal epithelium cells may  be involved in this inﬂam-
atory process as well. They express TNF- and eotaxin-3 that
re responsible for the recruitment of eosinophils in the oesoph-
gus. The crucial role of eotaxin-3 was demonstrated in a murine
odel as mice deﬁcient in the eotaxin receptor were protected from
xperimental EoE. Finally, eosinophils also produce thymic stromal
ymphoprotein (TSLP), a cytokine promoting Th2 differentiation.
This inﬂammatory process is summarized in Fig. 1. It induces an
esophageal remodelling which leads to oesophageal dysfunction
nd bolus impaction. Deposition of extracellular matrix proteins is
ssociated with subepithelial ﬁbrosis [8,9]. Eosinophils may con-
ribute to EoE pathogenesis by secreting tumour growth factor
TGF) 1 and eosinophil granulations. TGF1 is a cytokine involved
n epithelial growth, ﬁbrosis and tissue remodelling and has been
dentiﬁed in EoE. Some eosinophil granulations (eosinophil cationic
rotein, eosinophil peroxidase for example) may  have cytotoxic
ffects explaining epithelial cells death observed in EoE.
.2. Allergy
The concept of food allergens as a primary trigger of EoE was
ntroduced ﬁrst in a paediatric cohort by Kelly et al. [10]. Since then,
t has become increasingly clear that there was an allergic predis-
osition in the EoE population. A link has been described between
topy and EoE [11,12]. Allergic disorders (rhinitis, asthma, atopic
ermatitis) are encountered in up to 70% of adults with EoE [12].
In murine model, oesophageal eosinophilia was inducible by
llergens [13]. IL-13 and IL-5 were also found to be crucial for the
isease development [14]. As a consequence these experimental
ata support the concept that EoE represents an allergic disease in
hich T cells and eosinophils play key pathogenic roles.
In humans, relevant allergens have been identiﬁed for EoE. In
hildren EoE seems clearly to be a food antigen-driven disease.
n contrast aero-allergen sensitization has mainly been observed
n adults [6]. Seasonal exacerbations of EoE in spring and sum-
er  are in favour of a potential role of aero-allergens. Elevated
gE serum levels have been observed in EoE. They were speciﬁc to
ood and/or aero-allergens. Positive skin prick test have also been
oticed. Finally based on elimination diet and reintroduction test,
heat and milk were the most common allergens in a cohort of 50
dults (60% and 50% respectively) [15]. However, skin-prick testing
redicted only 13% of food association in this cohort.
.3. Genetics
Different studies have suggested genetic inheritability in EoE
6,16]. Sibling recurrence risk ratio was estimated around 80 in
oE [17]. Genome-wide analysis has identiﬁed a susceptibility locus
n chromosome 5q22 [18]. Thymic stromal lymphoprotein (TSLP)
ene is located on this locus. A genetic variant in the TSLP receptor
ene located on the pseudoautosomal region of the X-chromosome
as also linked with EoE in males [19]. Finally variations in TGF-
nd ﬁlaggrin genes have been also observed in EoE [19] as well as
xotoxin-3 gene polymorphism [20].
.4. Relation between GERD and eosinophiliaIt is well-known that GERD may  induce microscopic oesophagi-
is and eosinophilic inﬁltration [21,22]. This histological feature can
e reversed by proton pump inhibitors (PPIs) therapy [23]. Some
ata suggested that PPIs might also be effective to treat oesophagealFailure to thrive (paediatric < 2 years) Atopic dermatitis
Sleep disorders breathing
eosinophilia in absence of identiﬁed acid reﬂux [24]. Thus, a sub-
group of patients has been recently recognized: this was  named
“PPI responsive oesophageal eosinophilia” by the latest consensus
meeting [19]. These patients exhibit a typical EoE symptom pre-
sentation. GERD has been excluded and these patients demonstrate
a clinical and pathological response to PPIs. Different hypotheses
have been raised to explain this phenotype [19]. Healing of a dis-
rupted epithelial barrier may  prevent further immune activation.
Eosinophil longevity may  decrease on PPIs or PPIs may have some
anti-inﬂammatory properties. In vitro, PPIs might inhibit eotaxin-3
expression by oesophageal cells [25].
3. Clinical presentation
Patients with EoE may  present with a wide range of symptoms
including dysphagia, food impaction, heartburn and chest pain. The
clinical presentation may  be very different according to the age of
onset [19,26,27] (Table 1).
In adults, intermittent dysphagia for solids is the most typical
symptom of EoE (ranging from 25 to 100%) with long-lasting food
impaction representing the most frequent and severe presentation
of dysphagia [19,27]. In fact, it has been observed that 35–50% of
adults experienced at least one episode of food impaction requir-
ing emergent evaluation and endoscopic bolus removal during the
natural history of their disease [28,29]. It is not uncommon that
patients modify their chewing habits (i.e. eating food more slowly
and washing down solid food with liquids), thereby making the
clinical manifestations of EoE less evident and leading to delayed
diagnosis [30]. A minority of patients complain also of retrosternal
pain that may  occur spontaneously or after ingestion of alcohol,
acidic liquids or foods, particularly when food consistency is dry
or rough and/or when patients eat too fast. Other symptoms such
as nausea, vomiting or abdominal pain as well as diarrhoea and
weight loss can also occur [30–32].
In children younger than 2 years of age, feeding disorders
(refusal to eat, chewing problems, choking after liquids or solids
ingestion) and failure to thrive are dominant symptoms, while up
to the age of 12, vomiting, nausea, abdominal pain, water brash,
heartburn and regurgitation (GERD-like symptoms) are the most
common symptoms (ranging from 5 to 82%) [19,31–34]. Dyspha-
gia, food impaction, chest pain and diarrhoea were also reported
and their frequency usually increases with age [30–32].
Finally, patients with EoE may  also complain of additional atyp-
ical GERD symptoms such as asthma, hoarseness, cough, croup,
rhino-sinusitis, others ear-nose-throat (ENT) symptoms and sleep-
disordered breathing (ranging from 10 to 25%) [35,36].
No symptom in isolation is speciﬁc for the diagnosis of EoE.
Regardless of age, if a patient develops GERD-like symptoms and
does not respond to pharmacological or surgical treatment, EoE
should be strongly suspected [19].Finally EoE might be revealed by oesophageal complications
such as spontaneous perforation [19]. Perforation might be trans-
mural (Boerhaave’s syndrome) [37] or partial as intramural tears or
deep lacerations on endoscopy. These complications are rare and
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Fig. 1. Immunopathogenesis of eosinophilic oesophagitis (EoE). Eosinophilic oesophagitis is triggered by aero- and food allergens. The epithelial cells are activated by
interleukin (IL)-13. They contribute to the inﬂammatory process by secreting tumour necrosis factor (TNF)-, thymic stromal lymphoprotein and eotaxin-3. Thymic stromal
lymphoprotein promotes dendritic cells. Eotaxin-3 attracts eosinophils. Interleukin 13 helps B cells to produce immunoglobulin (Ig) E. Interleukin 9 activates mast cells which
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dapted from Straumann et al. [6].
ave been described only as clinical cases in the literature. Patients
ith spontaneous oesophageal perforation should be assessed for
oE.
. Diagnosis
.1. Upper endoscopy and histopathology
Upper endoscopy with oesophageal biopsies is the ﬁrst diagnos-
ic step in the work up of patients with suspected EoE as well as in
atients with dysphagia.
.1.1. Endoscopic features
A considerable number of endoscopic ﬁndings might be
bserved in EoE (Fig. 2). They include normal endoscopy, signs
f active inﬂammation such as mucosal oedema (pallor due to
ecreased vascular markings), exudates (whitish plaques), furrows
r signs of chronic inﬂammation with tissue remodelling such as
ings, stricture or crêpe-paper mucosa (mucosal fragility) [4,38].
hese different patterns may  co-exist in the same patient.
In a cohort of 261 patients who underwent upper oesophageal
ndoscopy for dysphagia, classic endoscopic ﬁndings (rings and/or
urrows) were absent in 13 of 31 patients (42%) with EoE [38]. Five
atients (16%) had completely normal endoscopic ﬁndings and 6
ad one single stricture or Schatzki ring, one had erosive oesophagi-
is and one presented diffuse oesophageal congestion. Conversely,
ings and/or furrows were identiﬁed in 14 patients whose biop-
ies did not meet the criteria for EoE. In another cohort, 10% of
atients with normal endoscopy had EoE on biopsies while only
8% of patients with endoscopic features suggestive of EoE had
osinophilic inﬁltration on biopsies [4]. Thus, endoscopic features
re neither sensitive nor speciﬁc of EoE. Biopsies sampling might
xplain some missed diagnosis of EoE. Moreover, the threshold to
iagnose EoE was 20 eosinophils per high power ﬁeld (hpf) in bothumour growth factor (TGF)- which stimulates ﬁbroblasts to produce extracellular
eroxidase) which damage epithelial cells.
studies, whereas this threshold is now 15 according to the consen-
sus meeting [19].
Recently, Hirano et al. proposed a standardized classiﬁcation
which incorporated the grading of 4 major oesophageal features
(rings, furrows, exudates, oedema) and the presence of addi-
tional features of narrow-calibre oesophagus, feline oesophagus
(or transient oesophageal rings), stricture and crêpe paper oesoph-
agus [39]. This score was named EREFS for Endoscopic Reference
Score for EoE but also for exudates, rings, oedema, furrows, and
stricture. Inter-observer agreement was  good for the 4 major
features of EoE (kappa = 0.40–0.54) and for stricture and crêpe
paper oesophagus (kappa = 0.52 and 0.58 respectively). It was  fair
for narrow-calibre oesophagus (kappa = 0.30) and poor for feline
oesophagus (kappa = 0.15). It remains to be determined if this score
might be used to evaluate EoE patients before and after treatment.
4.1.2. Histology
Eosinophils are not normally found in the oesophageal epithe-
lium and the quantity of intraepithelial eosinophils is a crucial
component in the diagnosis of EoE. According to the latest con-
sensus recommendations, 15 eosinophils/hpf is considered as the
minimal threshold for a diagnosis of EoE in both children and adults
[19]. The disease is limited to the oesophagus and other causes
of oesophageal eosinophilia should be excluded. The main causes
encompass eosinophilic gastro-enteritis, Crohn disease, and acha-
lasia [40]. As a consequence, it is reasonable to perform biopsies in
gastric antrum and duodenum to exclude other potential causes of
eosinophilia, especially in children.
The recent consensus acknowledged that a small number of
patients with EoE might have less than 15 eosinophils/hpf asso-
ciated with other features of eosinophilic inﬂammation such
as eosinophil microabscesses, superﬁcial layering of eosinophils,
extracellular eosinophil granules, basal cell hyperplasia, dilated
intercellular spaces, and lamina propria ﬁbrosis [19].
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Multiple biopsy specimens from the proximal and distal oesoph-
gus are required. Gonsalves et al. determined that one single
iopsy had a sensitivity of 55% and 5 biopsies a sensitivity of 100%
o diagnose EoE [41]. The consensus meeting recommended 2–4
iopsies in the proximal and 2–4 in the distal oesophagus [19].
.2. Allergy testing
The latest consensus conference on EoE recommends an evalu-
tion by an allergist or immunologist because of the high rates of
oncurrent allergic diseases such as asthma, rhinitis, eczema and
ood allergy [19]. Serum IgE and skin-prick testing for immediate-
ype food allergy is warranted to identify comorbid food-induced
llergic diseases in EoE patients. The consensus recommends per-
orming both serum IgE and skin-prick testing for aero-allergen
ecause of studies documenting aero-allergen sensitization and
easonal variability. However, as previously mentioned, the results
f skin tests were predictive of only 13% of food association detected
y elimination diet [15]. It remains to be determined if combin-
ng serum aero-and food allergen speciﬁc IgE and skin prick tests
n association with atopy patch tests (to detect non-IgE immune
eactions) might improve the predictive values of allergy testing
6]..3. Oesophageal pH-monitoring
Oesophageal pH-monitoring is useful to differentiate
osinophilia induced by acid from EoE. Molina Infante identiﬁed), rings (C) and crêpe paper oesophagus characterized by oesophageal tear (D).
35 adult patients with histological features of EoE in a cohort of 712
patients referred for upper endoscopy [24]. At baseline, pH testing
revealed that 15 of 21 (71%) patients without evidence of acid
damage on endoscopy had pathologic acid oesophageal exposure
whereas 6 did not. After 2 months of PPI therapy, 12 of 15 patients
(80%) with pathological reﬂux had resolution of oesophageal
eosinophilia suggesting that this histologic alteration might be
secondary to reﬂux. Three patients had persistent eosinophilia
suggesting that they might have GERD and EoE. Interestingly, 2
patients of 6 with normal baseline pH testing had resolution of
eosinophilia on PPIs. In these patients GERD diagnosis might have
been missed by pH testing at baseline or PPIs might have an effect
independent of gastric acid secretion inhibition. This entity was
recognized as PPI responsive oesophageal eosinophilia [19].
These results suggest that overlap may  exist between GERD and
EoE. As recommended by the latest consensus, oesophageal pH-
monitoring (or pH-impedance where available) is useful to evaluate
GERD in patients with oesophageal eosinophilia [19].
4.4. Other examinations
Barium swallow provides data on the length and diameter of
oesophageal strictures. It might be also useful to evaluate a narrow-
calibre oesophagus. Measuring oesophageal maximal diameter has
been shown to be a reproducible parameter to assess narrow-
calibre and to evaluate response to treatment [42]. However, its
correlation with dysphagia remains unclear.
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Fig. 3. High resolution manometry in a patient with eosinophilic oesophagitis. Pressure variations are recorded along the oesophagus and displayed as oesophageal pressure
topography plots. The x-axis is the time and the y-axis the length along the oesophagus. Pressure amplitudes are coded with a colour scale as presented on the right. Two
high  pressure zones are identiﬁed: the upper oesophageal sphincter (UES) and the oesophago-gastric junction (EGJ). Swallow is associated with upper oesophageal sphincter
and  oesophago-gastric junction relaxation and oesophageal contraction. In this patient with eosinophilic oesophagitis an early pan-oesophageal pressurization (deﬁned as
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Using endoscopic ultrasonography, a greater mucosal and mus-
ular thickness has been observed in patients with EoE compared
o controls [43,44]. The clinical utility of depicting muscle thickness
n EoE is not established. However, in clinical practice, an impor-
ant role of endoscopic ultrasonography might be to rule out other
auses of stricture in presentation with stenosis. It might be impor-
ant to eliminate an inﬁltrative process especially if there is no other
ndoscopic evidence of EoE.
Oesophageal manometry has been proposed to evaluate
esophageal function in patients with EoE. Using conventional sta-
ionary manometry, Nurko et al. identiﬁed abnormal peristalsis
n 41% of children with EoE [45]. Using high resolution manom-
try, oesophageal motility disorders were similarly distributed in
oE and GERD adult patients, thus limiting the role of manome-
ry in EoE [46]. Early pan-oesophageal pressurization (Fig. 3) was
ore frequently observed in EoE than in GERD and control subjects.
his pattern might be a hallmark of reduced oesophageal compli-
nce. However, it was encountered in only 17% of EoE patients.
inally, prolonged manometry recordings might be more relevant
han stationary examination to correlate episodes of dysphagia and
bnormal motor function [45].
Impedance planimetry (EndoFLIPTM, Crospon, Dangan, Galway,
reland) is a promising tool to manage patients with EoE. This
echnology uses a catheter with multiple impedance electrodes
nd a pressure sensor within a bag ﬁlled of conductive solution.
ressure and bag volume are measured during a distension proto-
ol and oesophageal and oesophago-gatric junction distensibilities
re calculated. Patients with EoE exhibited a signiﬁcant reduced
esophageal distensibility [47]. Oesophageal narrowing and local-
zed strictures were clearly detected. Future studies are required to
valuate the role of EndoFLIPTM in assessing oesophageal function
n response to therapy in EoE. oesophageal sphincter relaxation.
5. Treatment
A therapeutic algorithm is proposed in Fig. 4.
5.1. Medical treatment
5.1.1. Proton pump inhibitors
Recently several studies have demonstrated that there is an EoE
phenotype responding to PPI administration [24]. It is still unclear
whether this subgroup of patients represents a form of atypical
GERD, a variant of EoE responding to PPI therapy or a completely
separate entity [48]. However, as previously mentioned, the lat-
est consensus meeting recognized the PPI-responsive oesophageal
eosinophilia as a separate entity [19]. Finally PPIs inhibit eotaxin-3
expression in oesophageal cells [25].
Thus, it is fair to propose PPIs as ﬁrst line therapy for EoE or
suspected EoE and a double dose is usually prescribed for at least 8
weeks [49]. It is important to note that oesophageal pH monitoring
does not predict the response to PPIs [50].
5.1.2. Corticosteroids
As EoE is recognized as an inﬂammatory disease, cortico-
steroids are considered the ﬁrst-choice approach. Several trials
have shown the efﬁcacy of ﬂuticasone propionate and budes-
onide to control symptoms and to reduce eosinophilic inﬁltration
[34,48,51]. Topical administration (spray or oral viscous) is pre-
ferred to systemic due to similar efﬁcacy and fewer side effects
[52]. The dosage of ﬂuticasone ranged from 440 to 880 g twice
daily [53,54] and budesonide ranged from 1 to 2 mg  per day
[48]. Patients should be advised to rinse their mouth with water
and to avoid eating or drinking for at least 30 min  after tak-
ing these drugs in order to optimize contact with oesophageal
876 S. Roman et al. / Digestive and Liver Disease 45 (2013) 871– 878
Fig. 4. Therapeutic algorithm for eosinophilic oesophagitis (EoE) on the basis of current available evidence. The diagnosis of eosinophilic oesophagitis is based on the presence
of  at least 15 eosinophils per high power ﬁeld (hpf) on oesophageal biopsies and suggestive symptoms. Proton pump inhibitors (PPIs) are ﬁrst line therapy. Some authors
systematically proposed to repeat upper endoscopy and oesophageal biopsies after 8 weeks of proton pump inhibitors. Steroids and dietary therapy must be considered as
alternative ﬁrst-choice treatments. Endoscopic dilation may  be used in case of persistent oesophageal stenosis. Topical steroids must be preferred to systemic ones and their
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tiscous  formulations have been shown to provide better results than the nebulize
cceptable than the elemental one. It is worth of noting that so far there is no valid
ucosa. In a recent trial, viscous topical administration of budes-
nide was compared to topical nebulized administration [55].
iscous topical form was signiﬁcantly better than nebulized form
n controlling symptoms and histopathological abnormalities. The
uthors followed the distribution of budesonide mixed with
9mtechnetium-diethylenetriaminepentaacetic acid with nuclear
cintigraphy. This technique clearly documented that the viscous
ormulation guaranteed a higher mucosal contact time compared
o nebulized formulation. Moreover, the nebulized form was also
eposited in the lungs, while the viscous formulation was only
eposited in the digestive tract. As a consequence oral viscous for-
ulation should be preferred. To obtain a viscous form, budenoside
olution (1 mg/2 ml)  is mixed with sugar substitute (5 packets of
ucralose) [55,56].
The treatment duration is not well deﬁned. The usual duration
ith swallowed topical steroids is 6–12 weeks [57]. However, it has
een shown that EoE reappeared usually within 9 months in about
0% of patients after steroid discontinuation [58]. Straumann et al.
nvestigated the efﬁcacy of a long-term treatment with swallowed
udesonide at low dose (0.5 mg  per day) for 50 weeks in a ran-
omized, double-blind, placebo-controlled trial [59]. Budesonide
as more effective than placebo in maintaining histological and
linical remission. However, the overall success of budesonide was
nly partial as the regression of oesophageal eosinophilia and the
elief of symptoms occurred in about two-thirds and 50%, respec-
ively. Long-term treatment with this topical steroid was well
olerated. Further studies are necessary to deﬁne more precisely thellowed ones. Six-food elimination and targeted diets seem to be better and more
enance treatment for patients with eosinophilic oesophagitis.
formulation, the dosage and the duration of maintenance therapy
with oral budesonide.
Usually topical steroids are well tolerated. The most frequent
adverse event is represented by oesophageal candidiasis (0–32% of
patients enrolled in prospective studies) [48]. Finally the success of
steroid therapy seems to be similar in adults and children [9,19].
5.1.3. Other medical therapies
Montelukast is a leukotriene D4 receptor antagonist, which is
used in asthma. It was proposed in EoE and showed only partial efﬁ-
cacy in terms of symptom improvement [60]. A recent long-term
study showed that this drug was not able to maintain histopatho-
logical and clinical response achieved by topical steroids in adult
EoE patients [61].
Mepolizumab is a biological agent which selectively binds
and inactivates interleukin 5, a major player of the Th2 immune
response. A recent placebo-controlled trial on 11 patients with
EoE showed that this drug administered once every 4 weeks for
a total of 12 weeks was able to only partially reduce symptoms and
more markedly both peripheral and oesophageal eosinophilia [62].
A larger placebo-controlled study in 226 children or adolescents
with another IL-5 antibody, reslizumab, showed a signiﬁcant reduc-
tion in oesophageal eosinophilic inﬁltration without any effect on
symptoms [63].
Finally thiopurines have been used with success in very few
cases, but eosinophilia recurred rapidly after cessation of this ther-
apy [64].
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.2. Dietary therapy
As food allergens are implicated in the pathogenesis of EoE,
ietary elimination was proposed with various modalities: elemen-
al diet, targeted elimination diet and six-food elimination diet.
The elemental diet includes amino-acids, basic carbohydrates
nd medium chain triglycerides. It was associated with very good
esults in children [10,65]. Only one experience was  reported in
dults with limited beneﬁt (only 50% improvement) due to a likely
ack of compliance [66]. In fact, this diet is unpalatable and can
dversely impact quality of life. Moreover, it is expensive and may
equire an enteral feeding tube.
The targeted diet is based on the elimination of food allergens
dentiﬁed by means of allergy testing. The success of this kind of
ietary approach is good and ranges from 55 to 75% in children
34]. In adults, the use of targeted diet clearly needs further study.
he major limitation of this diet relies on the difﬁculty of accurately
etecting speciﬁc food allergens.
In order to overtake the limitations of targeted diet and to
ncrease the acceptability of dietary therapy, an empiric approach
ased on the elimination of the 6 most common food allergens (i.e.
ilk, egg, wheat, seafood, nuts and soy) has been proposed in both
hildren and adults [15,67]. In the study by Gonsalves et al., 64% of
dult patients exhibited an improvement in histologic alterations
nd 94% in symptoms after 6 weeks of diet [15]. The reintroduction
dentiﬁed milk and wheat as the most common allergens.
In summary, dietary therapy is conﬁrmed as a valid option to
ontrol symptoms and eosinophilic inﬁltration in both children and
dult populations. It can be considered as a fruitful alternative to
teroid treatment. To our knowledge, dietary therapy has not yet
een compared with topical corticosteroids in a large clinical trial.
otivated patient and consultations with dietician are mandatory
o ensure the success of dietary therapy.
.3. Endoscopic dilation
Endoscopic therapy of EoE is essential in case of food impaction
o remove the food responsible for symptoms. It has been also
roposed in dysphagic patients with oesophageal strictures or
arrow-calibre oesophagus despite medical treatment [68].
This therapeutic modality is certainly effective in relieving
ymptoms, but is not useful to reduce the degree of oesophageal
osinophilia [52]. Although the ﬁrst reports showed high rates of
erforations and mucosal tears [69], recent studies showed the
afety of the procedure [70–73]. The rare cases of perforation were
reated conservatively. The main complication was chest pain after
he procedure [68,73] and patient should be advised of this side
ffect.
Thus, endoscopic dilation might be considered as a second-line
reatment after failure of steroids or diet, if dysphagia persists and
esophageal stenosis or strictures are present [48,51].
. Conclusions
Eosinophilic oesophagitis is an emerging disease due to better
ecognition and increasing prevalence. Although there is some evi-
ence of food and aeroallergen roles in the development of the
isease, allergy testing was so far not predictive of eviction ther-
py success at least in adults. It represents an important challenge
or the future as identifying an allergen as causative agent might
e essential for EoE treatment. It remains to be determined if cur-
ent allergy testing lacks sensitivity or speciﬁcity or if factors other
han allergens are responsible for the symptoms. Different thera-
eutic approaches have been proposed. However these modalities
ave not been compared to each other and the choice of diet or
[ Disease 45 (2013) 871– 878 877
corticosteroids after the failure of PPI is usually based on patients’
preferences. A better understanding of EoE physiopathology and
determination of predictive factors for each treatment might be
helpful to guide patients’ choices. Finally another challenge for
the future will be to evaluate the role of maintenance therapy.
Presently it is not clear if maintenance therapy has a role in reduc-
ing oesophageal ﬁbrosis development in patients with EoE. Strategy
studies should be developed to compare maintenance therapy to
“on demand” therapy.
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